Chugai Pharmaceutical Co., Ltd.4519
▲ ポジティブ技術関連度
Chugai regains full rights to emugrobart and will restart development for spinal muscular atrophy after Roche halted obesity work.
資産への影響 2
Biotech & Genomic Medicine
Chugai Pharmaceutical Co., Ltd.Health Care
Roche Holding AGROP
▼ ネガティブ技術関連度
Roche discontinued development of emugrobart for obesity after interim Phase II data suggested weight-loss targets were unlikely to be met.